Jefferies Group LLC bought a new position in Xenon Pharmaceuticals Inc (NASDAQ:XENE) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 325,630 shares of the biopharmaceutical company’s stock, valued at approximately $4,298,000. Jefferies Group LLC owned about 1.69% of Xenon Pharmaceuticals at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the business. Vivo Capital LLC acquired a new position in Xenon Pharmaceuticals in the 3rd quarter worth about $18,552,000. Citadel Advisors LLC acquired a new position in Xenon Pharmaceuticals in the 3rd quarter worth about $9,952,000. Renaissance Technologies LLC increased its position in Xenon Pharmaceuticals by 7.7% in the 3rd quarter. Renaissance Technologies LLC now owns 527,337 shares of the biopharmaceutical company’s stock worth $6,961,000 after purchasing an additional 37,837 shares during the last quarter. Acuta Capital Partners LLC increased its position in Xenon Pharmaceuticals by 7.2% in the 3rd quarter. Acuta Capital Partners LLC now owns 482,500 shares of the biopharmaceutical company’s stock worth $6,369,000 after purchasing an additional 32,500 shares during the last quarter. Finally, Foresite Capital Management IV LLC acquired a new position in Xenon Pharmaceuticals in the 3rd quarter worth about $5,091,000. 69.71% of the stock is currently owned by institutional investors.
Shares of NASDAQ XENE opened at $7.31 on Friday. The company has a quick ratio of 29.36, a current ratio of 29.36 and a debt-to-equity ratio of 0.15. Xenon Pharmaceuticals Inc has a 52 week low of $2.35 and a 52 week high of $15.92.
Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.16). As a group, analysts forecast that Xenon Pharmaceuticals Inc will post -1.83 earnings per share for the current fiscal year.
Several research analysts have weighed in on the company. BidaskClub raised Xenon Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 5th. Zacks Investment Research lowered Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 11th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $16.00 price objective on shares of Xenon Pharmaceuticals in a report on Friday, August 10th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.33.
COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/12/08/jefferies-group-llc-buys-shares-of-325630-xenon-pharmaceuticals-inc-xene.html.
Xenon Pharmaceuticals Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.